Is Tarsus Pharmaceuticals Stock a Good Investment?
Tarsus Pharmaceuticals Investment Advice | TARS |
- Examine Tarsus Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Tarsus Pharmaceuticals' leadership team and their track record. Good management can help Tarsus Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Tarsus Pharmaceuticals' business and its evolving consumer preferences.
- Compare Tarsus Pharmaceuticals' performance and market position to its competitors. Analyze how Tarsus Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Tarsus Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Tarsus Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Tarsus Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Tarsus Pharmaceuticals is a good investment.
Sell | Buy |
Buy
Market Performance | Solid | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Tarsus Pharmaceuticals Stock
Researching Tarsus Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 91.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.28. Tarsus Pharmaceuticals recorded a loss per share of 3.75. The entity had not issued any dividends in recent years.
To determine if Tarsus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tarsus Pharmaceuticals' research are outlined below:
| Tarsus Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 17.45 M. Net Loss for the year was (135.89 M) with loss before overhead, payroll, taxes, and interest of (17.76 M). | |
| Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (117.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Tarsus Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Wall Street Analysts Believe Tarsus Pharmaceuticals Could Rally 41.09 percent Heres is How to Trade |
Tarsus Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Tarsus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tarsus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tarsus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Tarsus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Tarsus Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-09 | 2022-09-30 | -0.97 | -0.84 | 0.13 | 13 | ||
2024-05-08 | 2024-03-31 | -1.2 | -1.01 | 0.19 | 15 | ||
2023-03-13 | 2022-12-31 | -0.69 | -0.49 | 0.2 | 28 | ||
2024-11-07 | 2024-09-30 | -0.94 | -0.61 | 0.33 | 35 | ||
2021-11-09 | 2021-09-30 | -0.43 | -0.76 | -0.33 | 76 | ||
2022-08-11 | 2022-06-30 | -0.59 | -0.24 | 0.35 | 59 | ||
2021-08-04 | 2021-06-30 | -0.48 | 0.33 | 0.81 | 168 | ||
2021-05-11 | 2021-03-31 | -0.64 | 0.47 | 1.11 | 173 |
Know Tarsus Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tarsus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tarsus Pharmaceuticals backward and forwards among themselves. Tarsus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tarsus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Exoduspoint Capital Management, Lp | 2024-09-30 | 883 K | Ikarian Capital, Llc | 2024-06-30 | 800.3 K | Geode Capital Management, Llc | 2024-06-30 | 773.2 K | Artisan Partners Limited Partnership | 2024-06-30 | 627.6 K | Ensign Peak Advisors Inc | 2024-06-30 | 594.3 K | Polygon Management Ltd | 2024-06-30 | 500 K | Cormorant Asset Management, Llc | 2024-06-30 | 500 K | Lord, Abbett & Co Llc | 2024-06-30 | 463.2 K | Macquarie Group Ltd | 2024-06-30 | 455 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3.8 M | Rtw Investments, Llc | 2024-06-30 | 3.4 M |
Tarsus Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.78 B.Market Cap |
|
Tarsus Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | (0.63) | (0.66) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.69) | (0.66) |
Determining Tarsus Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Tarsus Pharmaceuticals is a good buy. For example, gross profit margin measures Tarsus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tarsus Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tarsus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tarsus Pharmaceuticals. Check Tarsus Pharmaceuticals' Beneish M Score to see the likelihood of Tarsus Pharmaceuticals' management manipulating its earnings.
Evaluate Tarsus Pharmaceuticals' management efficiency
Tarsus Pharmaceuticals has return on total asset (ROA) of (0.2726) % which means that it has lost $0.2726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5956) %, meaning that it created substantial loss on money invested by shareholders. Tarsus Pharmaceuticals' management efficiency ratios could be used to measure how well Tarsus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.55 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Tarsus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1.6 M in 2024, whereas Total Assets are likely to drop slightly above 165.9 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.70 | 4.02 | |
| Tangible Book Value Per Share | 6.57 | 4.01 | |
| Enterprise Value Over EBITDA | (3.05) | (3.20) | |
| Price Book Value Ratio | 3.02 | 3.17 | |
| Enterprise Value Multiple | (3.05) | (3.20) | |
| Price Fair Value | 3.02 | 3.17 | |
| Enterprise Value | 605.4 M | 635.7 M |
The strategic initiatives led by Tarsus Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.004 |
Basic technical analysis of Tarsus Stock
As of the 21st of November, Tarsus Pharmaceuticals has the Risk Adjusted Performance of 0.2027, coefficient of variation of 386.83, and Semi Deviation of 1.86. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tarsus Pharmaceuticals, as well as the relationship between them. Please validate Tarsus Pharmaceuticals information ratio and downside variance to decide if Tarsus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 46.4 per share. Given that Tarsus Pharmaceuticals has jensen alpha of 0.8511, we advise you to double-check Tarsus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.Tarsus Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tarsus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tarsus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tarsus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tarsus Pharmaceuticals' Outstanding Corporate Bonds
Tarsus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tarsus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tarsus bonds can be classified according to their maturity, which is the date when Tarsus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Tarsus Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Tarsus Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.2027 | |||
| Market Risk Adjusted Performance | 1.06 | |||
| Mean Deviation | 2.74 | |||
| Semi Deviation | 1.86 | |||
| Downside Deviation | 2.3 | |||
| Coefficient Of Variation | 386.83 | |||
| Standard Deviation | 3.62 | |||
| Variance | 13.12 | |||
| Information Ratio | 0.2322 | |||
| Jensen Alpha | 0.8511 | |||
| Total Risk Alpha | 0.5158 | |||
| Sortino Ratio | 0.365 | |||
| Treynor Ratio | 1.05 | |||
| Maximum Drawdown | 16.85 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 8.19 | |||
| Downside Variance | 5.31 | |||
| Semi Variance | 3.44 | |||
| Expected Short fall | (3.62) | |||
| Skewness | 1.05 | |||
| Kurtosis | 1.33 |
| Risk Adjusted Performance | 0.2027 | |||
| Market Risk Adjusted Performance | 1.06 | |||
| Mean Deviation | 2.74 | |||
| Semi Deviation | 1.86 | |||
| Downside Deviation | 2.3 | |||
| Coefficient Of Variation | 386.83 | |||
| Standard Deviation | 3.62 | |||
| Variance | 13.12 | |||
| Information Ratio | 0.2322 | |||
| Jensen Alpha | 0.8511 | |||
| Total Risk Alpha | 0.5158 | |||
| Sortino Ratio | 0.365 | |||
| Treynor Ratio | 1.05 | |||
| Maximum Drawdown | 16.85 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 8.19 | |||
| Downside Variance | 5.31 | |||
| Semi Variance | 3.44 | |||
| Expected Short fall | (3.62) | |||
| Skewness | 1.05 | |||
| Kurtosis | 1.33 |
Consider Tarsus Pharmaceuticals' intraday indicators
Tarsus Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tarsus Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tarsus Pharmaceuticals Corporate Filings
F3 | 15th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Tarsus Stock media impact
Far too much social signal, news, headlines, and media speculation about Tarsus Pharmaceuticals that are available to investors today. That information is available publicly through Tarsus media outlets and privately through word of mouth or via Tarsus internal channels. However, regardless of the origin, that massive amount of Tarsus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tarsus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tarsus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tarsus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tarsus Pharmaceuticals alpha.
Tarsus Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Tarsus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tarsus Pharmaceuticals Corporate Management
| Leonard JD | Chief Officer | Profile | |
| Scott Youmans | Vice Sales | Profile | |
| Seshadri Neervannan | Chief Officer | Profile | |
| Adrienne Kemp | Senior Communications | Profile | |
| Elizabeth MD | Chief Director | Profile | |
| Aziz MBA | Chief Officer | Profile |
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.